Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
  • Patent number: 10993958
    Abstract: Compositions comprising aldehyde functional monoterpenoids in combination with 3,3?,4?,7-tetrahydroxyflavone, zinc, and a 5-beta-D-Ribofuranosylpicolineamide adenine-dinucleotide molecule are provided for treating viral infections, e.g., coronavirus infections such as COVID-19.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: May 4, 2021
    Inventor: William B. Coe
  • Patent number: 10980772
    Abstract: Disclosed herein are “ketannabis” (or “ketonnabis”) compositions including a combination of: (1) tetrahydrocannabinol (THC); (2) a ketone body component such as beta-hydroxybutyrate (BHB) and/or acetoacetate; and (3) a dietetically or pharmaceutically acceptable carrier. Also disclosed herein are methods of using such ketannabis compositions for producing desired physiological effects. The ketannabis compositions beneficially enhance the euphoric effects of THC without aggravating common side effects or even acting to reduce common side effects such as anxiety, disruption of short-term memory, appetite increases, heart rate increases, and blood pressure changes.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: April 20, 2021
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10959979
    Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: March 30, 2021
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Abraham Karni, Orly Eizenberg
  • Patent number: 10952965
    Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: March 23, 2021
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Barrett Rabinow, Shawn F. Bairstow, Mahesh V. Chaubal, Sarah Lee, Jane Werling
  • Patent number: 10925918
    Abstract: A composition for food and a fat absorption inhibitor, each including a seaweed polyphenol and a tea extract.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: February 23, 2021
    Assignee: FUJIFILM Cornoration
    Inventors: Yuriko Oda, Fumitaka Ueda
  • Patent number: 10888574
    Abstract: The present disclosure relates to a method for suppressing obesity, which includes administering to a subject a compound represented by the following formula wherein n is an integer of 1 to 5; when n is 1, R1 is —OH or —O-glycosyl; when n is an integer of 2 to 5, one R1 is —OH and the other R1(s) is/are —O-glycosyl; and R2 is -glycosyl.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 12, 2021
    Assignee: KINJIRUSHI CO.. LTD.
    Inventors: Isao Okunishi, Tomoe Kato
  • Patent number: 10874634
    Abstract: Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: December 29, 2020
    Assignee: Queen's University at Kingston
    Inventors: Donald Andrew Cameron, Martin Petkovich, Toni Kristian Rantanen, Victor Snieckus, Johnathan Board, Suneel Singh, Ashishkumar Jayantilal Maheta
  • Patent number: 10849862
    Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: December 1, 2020
    Assignee: THERAVALUES CORPORATION
    Inventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
  • Patent number: 10844073
    Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 24, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
  • Patent number: 10786531
    Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: September 29, 2020
    Assignee: BMG PHARMA SPA
    Inventors: William A. Goolsbee, Jeffrey L. Lillard
  • Patent number: 10765660
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 8, 2020
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
  • Patent number: 10766872
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 8, 2020
    Assignee: The Board Institute, Inc.
    Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
  • Patent number: 10744114
    Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: August 18, 2020
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Han Soo Kim, Ho Sup Yoon
  • Patent number: 10729674
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: August 4, 2020
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Patent number: 10703699
    Abstract: In one embodiment, the present application discloses compositions and methods of solubilizing pterostilbene or resveratrol, or mixture thereof in aqueous media.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 7, 2020
    Assignee: Ironstone Separations, Inc.
    Inventors: James D. McChesney, Igor Nikoulin, Douglas L. Rodenburg
  • Patent number: 10688116
    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: June 23, 2020
    Inventors: Dania Birte Reiche, Nicole Mohren, Laura Johnston, Bruce Somerville, Rebecca K. Voth
  • Patent number: 10668088
    Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 2, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Shuen Ei Chen, Thau Kiong Chung, Daniel Raederstorff, Wolfgang Schalch
  • Patent number: 10668157
    Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 2, 2020
    Assignees: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Haruka Obata, Kiyoshi Shoji, Yoshiko Yamazaki, Toru Matsunaga, Takao Sato, Wakiko Asayama, Shinichi Yasueda
  • Patent number: 10646465
    Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 12, 2020
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Michal Abraham, Orly Eizenberg
  • Patent number: 10646467
    Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of PRO-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 12, 2020
    Inventors: Tak-Hang Chan, Chi-Chiu Wang
  • Patent number: 10632098
    Abstract: The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chiysoeriol, Cosmosiin and Flavocannabiside or their synthases, for the prevention and treatment of certain ocular diseases and related disorders.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: April 28, 2020
    Inventors: Henry I C Lowe, Ngeh J. Toyang
  • Patent number: 10626109
    Abstract: The present invention relates to fungicidal N-hetarylcarbonyl-2-(benzocycloalken-1-yl)piperidines or pyrrolidines of formula (I), and their thiocarbonyl derivatives, wherein A represents a carbo-linked, unsaturated or partially saturated, 5-membered heterocyclyl group that can be substituted by up to four groups R that can be the same or different; T represents 0 or S; n represents 1 or 2; m represents 1, 2 or 3; p represents 1, 2, 3 or 4, L1 and L2 independently represent CZ4Z5, NZ6, 0, S, S(O) or S(0)2; and R and Z1-Z6 are as defined in the claims; their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 21, 2020
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Philippe Desbordes, Philippe Rinolfi, Tomoki Tsuchiya
  • Patent number: 10603349
    Abstract: The present invention relates to a method for preparing a granulate composition of rhizomes from Alpinia galanga or Alpinia conchigera having a high and stable content of 1?S-1?-acetoxychavicol acetate and low microbiological count, which is suitable for preparing orally ingestible dosage forms such as tablets or capsules.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: March 31, 2020
    Assignee: NERTHUS APS
    Inventors: Henrik Byrial Jakobsen, Ina Giversen
  • Patent number: 10596185
    Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 levels, treating inflammation, and treating symptoms of metabolic syndrome.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: March 24, 2020
    Assignees: INGREDIENTS BY NATURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
    Inventors: Robert M. Brewster, John A. Manthey
  • Patent number: 10548938
    Abstract: The object is to provide a method of manufacturing a fraction containing nobiletin and tangeretin at high concentrations, which is excellent in terms of safety, economic efficiency, and the potential for industrialization. The method includes (1-1) a step of treating citrus fruit with hot water to obtain a hot water-treated product; (1-2) a step of drying the hot water-treated product to obtain a dried product; (1-3) a step of treating the dried product with a solvent capable of dissolving nobiletin and tangeretin to obtain a nobiletin and tangeretin solution; (3) a step of concentrating and/or drying the nobiletin and tangeretin solution to obtain a nobiletin and tangeretin concentrate; and (4) a step of treating the nobiletin and tangeretin concentrate with a dilute alkali to obtain a composition containing nobiletin and tangeretin as an insoluble component, and by a composition containing nobiletin and tangeretin at high concentrations manufactured by the method.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: February 4, 2020
    Assignees: UNIVERSITY OF THE RYUNKYUS, OKINAWA RESEARCH CENTER CO., LTD.
    Inventors: Toshiaki Teruya, Yuto Teruya, Saki Sugiyama, Je-Tae Woo
  • Patent number: 10543277
    Abstract: A medicinal composition useful for the treatment of head and neck cancer premalignant lesions. The composition includes a curcuminoid mixture and an essential oil of turmeric. The curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin. The essential oil of turmeric includes about 45% ar-turmerone. The weight ratio of curcuminoid mixture to essential oil of turmeric ranges from about 1:3 to about 99:1. Methods of preparation of the composition is provide. Methods of treatment of head and neck cancer premalignant lesions by oral administration is provided.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: January 28, 2020
    Assignee: ARJUNA NATURAL PRIVATE LIMITED
    Inventors: Benny Antony, Moni Abraham Kuriakose
  • Patent number: 10544157
    Abstract: The present invention provides a process for the preparation of darunavir or solvates or a pharmaceutically acceptable salt thereof substantially free of bisfuranyl impurities, particularly darunavir propionate solvate. The present invention also provides a process for preparation amorphous darunavir using the darunavir propionate solvate.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: January 28, 2020
    Assignee: LAURUS LABS LIMITED
    Inventors: Kameswar R. Chivukula, Venkata R. Murthy, Venkata S. Indukuri, Seeta R. Gorantla
  • Patent number: 10537547
    Abstract: Disclosed are methods of favouring epithelial wound healing in a subject. Wounds suitable for this method include wounds located on the skin or in a cornea The methods comprise contacting a wound with an activator of an AKT pathway and/or an inhibitor of the MAPK pathway such as CREB inhibitors. Preferred compounds include SC-79, C646, curcumin, platelet-derived growth factor, 4?chloro-3-hydroxy-2-naphthanilide and fumonisin B. A model for wound healing is also disclosed. The model can be used to identify test compounds that are AKT activators or inhibitors of MAPK pathway, which are suitable to favoring epithelial wound healing.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 21, 2020
    Inventors: Sylvain Guerin, Lucie Germain, Karine Zaniolo, Camille Couture, Pascale Desjardins
  • Patent number: 10500145
    Abstract: A temporary tattooing ink is produced from concentrated genipin. In one embodiment, the concentrated genipin forms part of a solution. In another embodiment, the genipin is provided in a gel form which also includes a solvent and a thickening agent. Finally, an applicator is described into which genipin may be embedded for applying to a user's skin.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 10, 2019
    Assignee: inkbox ink inc.
    Inventors: Tyler James Handley, Braden Handley, Christopher Blain Caputo, Adam Manuel Zrehen
  • Patent number: 10391113
    Abstract: Disclosed are a compound pharmaceutical composition containing Cichorium glandulosum Boiss et Hout as a lipid-lowering active ingredient and the use of the composition for preparing a drug for treating or preventing lipid metabolism disorders, wherein the composition comprises a pharmaceutically active ingredient and a pharmaceutically acceptable carrier, wherein the pharmaceutically active ingredient consists of quercetin-3-O-?-D-glucuronoside, isoquercitrin and quercetin at a molar ratio of 1.1-2.4:1.3-3.3:1.2-3.1.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: NANJING RUIYING RUNZE BIOPHARMAEUTICAL TECHNOLOGY CO., INC.
    Inventors: Jing Shang, Lin Ding, Guohong Qin, Tao Wang, Jun Liu, Yu Li, Ting He
  • Patent number: 10392400
    Abstract: Provided herein are palladium-mediated coupling reactions useful in the preparation of ketone-containing organic molecules. The provided methods can be used for the preparation of natural products and pharmaceutical agents, including Eribulin, halichondrins, and analogs thereof. The present invention also provides novel halichondrin analogs which can be prepared via the palladium-mediated coupling reactions. The novel halichondrin analogs can be used in the prevention and/or treatment of diseases or conditions (e.g., proliferative diseases such as cancer).
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 27, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Jung Hwa Lee, Yoshito Kishi, Ayumi Osawa, Zhanjie Li
  • Patent number: 10392361
    Abstract: The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl)chromans of formula I. The intermediates thus obtained can be used for the synthesis of Nebivolol.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 27, 2019
    Assignee: Menarini International Operations Luxembourg S.A.
    Inventors: Sandra Bartoli, Serena Mannucci, Alessio Griselli, Alessio Stefanini
  • Patent number: 10369132
    Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 6, 2019
    Assignee: MEI PHARMA, INC.
    Inventor: Ofir Moreno
  • Patent number: 10370350
    Abstract: The present disclosure relates to salts of the compound (I), polymorphic forms thereof, methods for preparation and use thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 6, 2019
    Assignee: Research Development Foundation
    Inventors: Michael O'Neill, Barbara Kidon, Thomas Adkins, Hongqiao Wu, Emmanuel T. Akporiaye
  • Patent number: 10370364
    Abstract: A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: wherein R1 is a substituted or unsubstituted C1-5 linear or branched alkyl, a C5-6 cycloalkyl, a C5-6 cycloalkyl containing at least one heteroatom selected from among O and N, a substituted or unsubstituted C6-12 aryl, or a C5-6 heteroaryl containing at least one heteroatom selected from among O and N; R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; and R3 to R5 are each independently hydrogen, hydroxyl, methyl, methoxy, acetoxy, carboxy or benzoyloxy.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: August 6, 2019
    Assignee: OSTEONEUROGEN INC.
    Inventors: Byung Soo Youn, Jun Hwan Kim, Han Soo Kim, Ho Sup Yoon, Ik Hwan Kim
  • Patent number: 10342777
    Abstract: A caffeoylquinic acid-rich extract obtained from Erigeron multiradiatus and a method for producing the same. A caffeoylquinic acid-rich extract includes at least 15% by weight of a mixture of certain caffeoylquinic acids. The extract with the mixture of caffeoylquinic acids is highly efficacious in treating and preventing myocardial ischemia or myocardial ischemia reperfusion injuries. A method for treating or preventing a disease caused by myocardial ischemia or myocardial ischemia reperfusion includes administering a therapeutically effective amount of the caffeoylquinic acid-rich extract to a subject. Pharmaceutical compositions including the caffeoylquinic acid-rich extract are also disclosed.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: July 9, 2019
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Pei Luo, Zhifeng Zhang, Hao Zhang
  • Patent number: 10322130
    Abstract: The present invention provides PI3K protein kinase modulators of formula wherein R, Cy1, R1, R2, L1 and Cy2 are as defined herein. The present invention also relates to methods of preparing compounds of formula (I) to pharmaceutical compositions containing them and to methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: June 18, 2019
    Assignee: RHIZEN PHARMACEUTICALS SA
    Inventors: Dhanapalan Nagarathnam, Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Srikant Viswanadha, Govindarajulu Babu, Prashant K. Bhavar
  • Patent number: 10316053
    Abstract: The present disclosure provides a compound of the following formula, racemates, enantiomers, prodrugs and salts thereof: Also provided is the use of these compounds for the treatment of ischemia and reperfusion injuries. Further applications include the treatment of diseases caused by cell apoptosis and/or cell necrosis.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 11, 2019
    Assignee: ARMARON BIO PTY LTD
    Inventor: Grant McLachlan
  • Patent number: 10314810
    Abstract: Provided herein are novel agents that modulate AhR activity for use in therapeutic compositions and methods thereof for inhibiting cancer cell proliferation and tumor cell invasion and metastasis. The agents comprise AhR inhibitors or non-constitutive AhR agonists of Formula (I) and (II) for the inhibition of cancer cell growth and parameters that characterize tumor metastasis, such as tumor cell invasiveness.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: June 11, 2019
    Assignees: Trustees of Boston University, Northeastern University, Boston Medical Center Corporation
    Inventors: David H. Sherr, Michael Pollastri, Jennifer Schlezinger, Sarah Haigh Molina, Scott Schaus, Joshua Robert Giguere
  • Patent number: 10294239
    Abstract: The present invention relates to processes for the preparation of an ertugliflozin-L-pyroglutamic acid (1:1) and co-crystal ertugliflozin-L-proline (1:1) co-crystal. The present invention further relates to an ertugliflozin-L-proline (1:2) co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: May 21, 2019
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Ramkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri
  • Patent number: 10238625
    Abstract: Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 26, 2019
    Assignee: RESPIVANT SCIENCES GMBH
    Inventors: William Gerhart, Pravin Soni, Ahmet Tutuncu
  • Patent number: 10206901
    Abstract: A nasal spray composition and method for treating convulsive seizures, including epileptic seizures, and also autism behavioral events. In embodiments, the nasal spray composition contains delta-9-tetrahydrocannabinol and, optionally, terpenes such as linalool.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: February 19, 2019
    Assignee: JC Pharma, Inc.
    Inventors: Jason Allen Cranford, Donald Channing Cooper
  • Patent number: 10188747
    Abstract: The technology described herein is directed to agonists of, e.g. Esr2, Dlx5, and/or Egr3, for the inhibition of cancer cells (e.g. squamous carcinoma cancer cells) and the treatment of cancer.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 29, 2019
    Assignee: The General Hospital Corporation
    Inventors: Gian Paolo Dotto, Yang Sui Brooks
  • Patent number: 10105346
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: October 23, 2018
    Assignee: MEI PHARMA, INC.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Patent number: 10105344
    Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: October 23, 2018
    Assignee: Stokely-Van Camp, Inc.
    Inventors: Jeffrey J. Zachwieja, Mark Arthur Pirner, JohnEric William Smith
  • Patent number: 10098915
    Abstract: An equol-producing lactic acid bacteria-containing composition comprises, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is effective for the prevention and alleviation of malaise inclusive of climacteric disturbance in middle-aged and elderly women for which no effective prophylactic method or alleviating means has heretofore been available.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 16, 2018
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeto Uchiyama, Tomomi Ueno, Toshimi Suzuki
  • Patent number: 10072055
    Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: September 11, 2018
    Assignee: Resother Pharma APS
    Inventors: Angelo P. Consalvo, Nozer M. Mehta, Mauro Perretti, Jesmond Dalli
  • Patent number: 10045961
    Abstract: Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: August 14, 2018
    Assignee: Drexel University
    Inventors: Jinhong Chang, Fang Guo, Timothy M. Block, Ju-Tao Guo
  • Patent number: 10039739
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: August 7, 2018
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Patent number: 10039725
    Abstract: A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 7, 2018
    Assignees: ChromaDex Inc., The Regents of the Unviersity of California
    Inventors: Jeremy Bartos, Ryan Dellinger